Canaccord lowered the firm’s price target on Zevra Therapeutics to $22 from $24 and keeps a Buy rating on the shares. The firm said with a recent raise and 2Q24 results behind them, they now await potential FDA approval on the company’s arimoclomol for Neimann-Pick type C (NPC), which has an action date of September 21, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics presents data for arimoclomol, OLPRUVA at SSIEM 2024
- Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
- Zevra Therapeutics to Participate at Upcoming Investor Conferences
- Zevra Therapeutics reports Q2 EPS (48c), consensus (43c)
- Zevra Therapeutics Inc options imply 8.4% move in share price post-earnings